药英教学资料（南京医科大学）RECENT ADVANCES WITH LIPOSOMES AS PHARMACEUTICAL CARRIERS.pdfVIP

R E V I E W S RECENT ADVANCES WITH LIPOSOMES AS PHARMACEUTICAL CARRIERS Vladimir P. Torchilin Abstract | Liposomes — microscopic phospholipid bubbles with a bilayered membrane structure — have received a lot of attention during the past 30 years as pharmaceutical carriers of great potential. More recently, many new developments have been seen in the area of liposomal drugs — from clinically approved products to new experimental applications, with gene delivery and cancer therapy still being the principal areas of interest. For further successful development of this field, promising trends must be identified and exploited, albeit with a clear understanding of the limitations of these approaches. RETICULO-ENDOTHELIAL Since the pioneering observation of Alec Bangham improvement in survival1–3. The same set of indications SYSTEM roughly 40 years ago that phospholipids in aqueous was targeted by a combination therapy comprising The physiological system systems can form closed bilayered structures, lipo- liposomal doxorubicin and paclitaxel4 or Caelyx responsible for the elimination somes have moved a long way from being just another (Schering-Plough)(doxorubicin in PEG liposomes) of foreign macromolecules and exotic object of biophysical research to become a and carboplatin5. Caelyx is also in Phase II clinical tria